{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibwmczp2jmv5k3jjw3bxdjqmi4uunlfaaaprwebhuoksy62thg4nq",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mghd7pmszif2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihs4yniv5gslv4xxwpwazmdqvpsj3sble4olz6hvbzdguafle3ihy"
    },
    "mimeType": "image/jpeg",
    "size": 123080
  },
  "path": "/pharmalot/2026/03/06/fda-uniqure-china-pfizer-obesity-antibiotics/?utm_campaign=rss",
  "publishedAt": "2026-03-06T14:25:38.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Pharmalot",
    "pharmalittle",
    "STAT+"
  ],
  "textContent": "China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more crowded",
  "title": "STAT+: Pharmalittle: We’re reading about an FDA-UniQure tussle, a Pfizer obesity drug approval in China, and more",
  "updatedAt": "2026-03-06T14:25:42.000Z"
}